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We report on a case in which a combination of an insulin infusion and plasma exchange were successfully used in the acute 
management of hyperlipaemic pancreatitis.
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Introduction
Acute pancreatitis (AP) is an infrequently encountered potentially 
fatal complication of severe hypertriglyceridaemia, with a 5% 
mortality rate.1 Hypertriglyceridaemia is the causative factor in 
up to 7% of cases of AP, and the third most common cause after 
alcohol and gallstones.2,3 Few case reports have been published 
on the specific modalities in the acute management of 
hyperlipaemic pancreatitis. The role of modalities, such as insulin 
and heparin, as well as plasma exchange, in the management of 
severe hypertriglyceridaemia is not yet clear. We report on a case 
in which concurrent insulin and plasma exchange was a 
successful treatment modality in the acute management of 
hyperlipaemic pancreatitis.
Case study
A 32-year-old female patient, known to have psoriatic arthritis, 
presented with a two-week history of severe epigastric pain 
radiating to her back, accompanied by nausea, vomiting and 
fever, and a history of starting the anti- tumour necrosis factor 
(TNF) agent, infliximab, two months before presentation. She 
had been diagnosed with pancreatitis two weeks prior to 
admission to our facility. During admission, the infliximab was 
discontinued and the patient improved. She was a smoker and 
reported that her father had had a fatal myocardial infarction 
aged 40  years. There was no specific mention of familial 
hypertriglyceridaemia. She was not diabetic. The patient was not 
pregnant and denied alcohol use. A physical examination 
revealed epigastric tenderness. There was no eruptive xanthoma, 
nor hepatosplenomegaly. The laboratory investigation revealed 
serum amylase levels of 562  IU/l (normal 25–125  IU/l), serum 
lipase levels of 777 IU/l (normal 13–60 IU/l), urine amylase levels 
of 3 611  IU/l (normal 0–490  IU/l), C-reactive protein levels of 
2.1 mg/l (normal < 5.0 mg/l), serum triglycerides of 60.5 mmol/l 
(normal 0.4–1.6  mmol/l) and normal liver function. Urine 
pregnancy testing was negative. Computed tomography (CT) 
showed oedema of the pancreas with excessive phlegmon 
formation, free fluid in the pelvis and bilateral pleural effusions 
(Figure 1). There were no signs of stones in the biliary ducts, nor 
any ductal dilatation.
A diagnosis of severe hypertriglyceridaemia complicated by AP 
was made. The anti-TNF agent was implicated as the most likely 
underlying cause. The patient was admitted to the intensive care 
unit, where she received an insulin infusion and two sessions of 
plasmapheresis, in addition to standard therapy for AP which 
included intravenous analgesia and rehydration. She was made 
to fast for two days, after which she followed an extremely low-
fat diet. Her triglyceride levels decreased to 4.5  mmol/l within 
three days, at which point bezafibrate was introduced at 400 mg 
per day (Figure 2.) Infliximab was not reintroduced.
Discussion
Patients with triglyceride levels of ≥ 11.3  mmol/l are at risk of 
developing AP.4 Five per cent of these patients develop AP as a 
result of the hypertriglyceridaemia.5 Many factors contribute to 
pancreatic damage in patients with triglyceride levels in excess 
of 11.3 mmol/l. The leakage of pancreatic lipase causes hydrolysis 
of the triglycerides and degradation of the chylomicrons, forming 
proinflammatory free fatty acids, leading to endothelial damage. 
Chylomicrons are large triglyceride-rich lipoproteins, and when 
present in large quantities can interfere with pancreatic capillary 
blood flow owing to hyperviscosity, thereby leading to ischaemic 
changes in the acini. This process leads to accelerated pancreatic 
tissue necrosis.5,6 Hyperlipaemic pancreatitis is a potential 
complication of primary (genetic), as well as secondary, disorders 
of lipid metabolism. Secondary hypertriglyceridaemia has been 
documented in the presence of a number of conditions, 
including diabetes mellitus, pregnancy, hypothyroidism, 
excessive alcohol intake and nephrotic syndrome, as well as the 
use of a number of drugs, including hormone replacement 
drugs, selective oestrogen receptor modulators, certain 
antiretroviral agents, retinoids, thiazides, beta blockers and 
propofol.7
Although conventional interventions in AP are of paramount 
importance, specific therapies for acute severe hyperlipaemic 
pancreatitis are still unclear. Supportive therapy of any AP 
aetiology includes aggressive hydration, analgesia, nutritional 
support, restriction of the exogenous triglycerides and 
monitoring in a high care environment.8 Proposed specific 
modalities in the acute management of hyperlipaemic 
pancreatitis include plasma exchange and the use of heparin 
and insulin.9,10 However, consensus guidelines do not exist, 
randomised control studies are lacking and experience is limited 
to case reports.
The goal of acutely lowering triglyceride levels in hyperlipaemic 
pancreatitis is to prevent complications, such as necrotising 
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pancreatitis, organ failure and death. First-line drugs, such as 
fibrates, omega-3 fatty acids, statins and niacin, do not lower 
triglyceride levels rapidly, owing to their slow onset of action. For 
this reason, the early initiation of specific interventions, including 
the use of heparin, insulin infusions and plasma exchange, has 
been recommended.
Both insulin and heparin stimulate the release of lipoprotein 
lipase (LPL), therefore decreasing levels of circulating triglycerides. 
Many no longer favour the use of heparin, as the effect on 
increasing LPL activity has been shown to peak transiently, and 
ultimately result in a decrease in LPL activity, leading to raised 
triglyceride levels.5
Plasma exchange is an extracorporeal method, employed to 
rapidly remove triglycerides from the circulation, thereby 
preventing the formation of free fatty acids. The removal of toxic 
proteases is another postulated benefit of plasma exchange.11 
The early initiation of plasma exchange was revealed to deliver 
the best results in a few retrospective analyses.12,13 In 2014, 
Gubensek et al. conducted an observational study in which 111 
episodes of hyperlipaemic pancreatitis in 103 patients were 
analysed. They found that plasma exchange reduced triglyceride 
levels within the first two days. This was found to occur sooner 
than both conservative management and treatment with heparin 
and insulin. A low complication and mortality rate was also 
demonstrated.1
Although the use of plasma exchange in rapidly lowering 
triglyceride levels has been described in many case reports, the 
number of plasma exchange sessions required to lower 
triglyceride levels remains unclear.1,14 Taking all the available 
published literature into consideration, we elected to treat our 
patient with a combination of an insulin infusion and two sessions 
of plasma exchange, where we removed 3 l of plasma, and 
replaced it with 5% human albumin, without fresh frozen plasma. 
The plasma exchange was initiated within 12 hours of 
presentation, in addition to the standard management of AP, and 
achieved a 74% reduction in triglyceride levels within 72 hours. 
Both insulin infusion and plasma exchange are effective in acutely 
lowering circulating triglycerides. However, experience with the 
concomitant use of plasma exchange and insulin is limited. We 
concede that there is uncertainty as to which therapeutic 
modality resulted in the rapid reduction of serum triglycerides in 
our patient. Head-to-head trials are required which compare the 
use of insulin infusion alone, plasma exchange alone, and a 
combination of the two, to establish evidence-based guidelines 
on the acute management of this life-threatening condition. A 
significant lowering of triglyceride levels by Gaudet et al., using a 
selective antisense inhibitor of apolipoprotein C-III (ApoCIII), was 
demonstrated in a very recent publication.15 They achieved a 
mean reduction in triglyceride levels of 71% after 13 weeks of the 
subcutaneous administration of the antisense inhibitor of ApoCIII.
Conclusion
A new modality in the treatment of patients with severe 
hypertriglyceridaemia who are at risk of serious complications, 
including hyperlipaemic pancreatitis, is now available. However, 
long-term data and head-to-head comparisons with existing 
modalities are required.
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Figure 1: A computed tomography scan of the abdomen, showing 
oedema of the pancreas, particularly the head of the pancreas (arrow) 
with phlegmon formation and free fluid in the abdomen, favouring a 
radiological diagnosis of acute pancreatitis.
Figure 2: The rapid decline in serum triglyceride levels in response to 
specific modalities.
Note: The first session of plasma exchange and insulin infusion were commenced 
within 12 hours of the diagnosis (white arrow). The second session of plasma 
exchange was performed at 36 hours (grey arrow). Bezafibrate was introduced on 
day 3 (black arrow).
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